H.C. Wainwright Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $34

Moomoo NewsMar 1 05:33 ET · Ratings

RBC Capital Adjusts Viridian Therapeutics Price Target to $46 From $47, Maintains Outperform - Speculative Risk Rating

MT NewswiresFeb 28 09:34 ET · Ratings

A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $27 to $46

Moomoo NewsFeb 28 08:00 ET · Ratings

Viridian Therapeutics Positioned for Market Leadership With Strategic Advancements and Competitive Edge

TipRanksFeb 27 14:25 ET

Viridian Therapeutics: Strong TED Trial Results and Promising Pipeline Drive Buy Rating

TipRanksFeb 27 11:05 ET · Ratings

Viridian Therapeutics' Q4 Net Loss Narrows, Revenue Flat

MT NewswiresFeb 27 09:26 ET